Nothing Special   »   [go: up one dir, main page]

YU37902A - Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3- benzazocini i njihova primena kao lekova - Google Patents

Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3- benzazocini i njihova primena kao lekova

Info

Publication number
YU37902A
YU37902A YU37902A YUP37902A YU37902A YU 37902 A YU37902 A YU 37902A YU 37902 A YU37902 A YU 37902A YU P37902 A YUP37902 A YU P37902A YU 37902 A YU37902 A YU 37902A
Authority
YU
Yugoslavia
Prior art keywords
benzazocines
methano
hexahydro
medicaments
substituted
Prior art date
Application number
YU37902A
Other languages
English (en)
Inventor
Adrian Carter
Helmut Ensinger
Wolfram Gaida
Matthias Grauert
Joachim Mierau
Thomas Weiser
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU37902A publication Critical patent/YU37902A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pronalazak se odnosi na supsitutuisane 1,2,3,4,5,6-heksahldro-2,6-metano-3-benzazocine opšte formule (1), u kojoj ostaci R1, R2, R3,R4, R5, R6, X i A mogu da imaju značenja koja su navedena u opisu i u zahtevima, na postupak za njihovo pripremanje, kao i na njihovu primenu kao lekova. [The invention relates to substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of the general formula (1), wherein the groups R1, R2, R3, R3', R4, R5, R6, X and A are defined as per the description and claims, to a method for their production and to the use thereof as medicaments.
YU37902A 1999-11-27 2000-11-21 Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3- benzazocini i njihova primena kao lekova YU37902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19957156A DE19957156A1 (de) 1999-11-27 1999-11-27 Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
YU37902A true YU37902A (sh) 2005-07-19

Family

ID=7930562

Family Applications (1)

Application Number Title Priority Date Filing Date
YU37902A YU37902A (sh) 1999-11-27 2000-11-21 Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3- benzazocini i njihova primena kao lekova

Country Status (33)

Country Link
EP (1) EP1235809B1 (sh)
JP (1) JP2003519687A (sh)
KR (1) KR20020058042A (sh)
CN (1) CN1177825C (sh)
AR (1) AR026586A1 (sh)
AT (1) ATE254108T1 (sh)
AU (1) AU5789701A (sh)
BG (1) BG106682A (sh)
BR (1) BR0015786A (sh)
CA (1) CA2383114C (sh)
CO (1) CO5251469A1 (sh)
CZ (1) CZ20022120A3 (sh)
DE (2) DE19957156A1 (sh)
DK (1) DK1235809T3 (sh)
EA (1) EA005681B1 (sh)
EE (1) EE200200267A (sh)
ES (1) ES2210036T3 (sh)
HK (1) HK1052176A1 (sh)
HR (1) HRP20020460A2 (sh)
HU (1) HUP0204169A3 (sh)
IL (1) IL149607A0 (sh)
MX (1) MXPA02003822A (sh)
NO (1) NO20022457L (sh)
NZ (1) NZ519758A (sh)
PL (1) PL355493A1 (sh)
PT (1) PT1235809E (sh)
SK (1) SK9302002A3 (sh)
TR (1) TR200302031T4 (sh)
UA (1) UA72566C2 (sh)
UY (1) UY26448A1 (sh)
WO (1) WO2001051471A1 (sh)
YU (1) YU37902A (sh)
ZA (1) ZA200204056B (sh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (de) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
JP6400592B2 (ja) * 2012-11-09 2018-10-03 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19907874A1 (de) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma N-(5-Phenyl-tetrahydrofuranyl)methyl- und N-(6-Phenyl-tetrahydropyranyl)methyl substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CZ20022120A3 (cs) 2002-09-11
UA72566C2 (uk) 2005-03-15
HK1052176A1 (en) 2003-09-05
EP1235809B1 (de) 2003-11-12
KR20020058042A (ko) 2002-07-12
BG106682A (bg) 2003-01-31
EP1235809A1 (de) 2002-09-04
HUP0204169A2 (hu) 2003-03-28
CO5251469A1 (es) 2003-02-28
PL355493A1 (en) 2004-05-04
NO20022457D0 (no) 2002-05-24
NZ519758A (en) 2004-05-28
TR200302031T4 (tr) 2004-01-21
CN1399630A (zh) 2003-02-26
AU5789701A (en) 2001-07-24
CA2383114A1 (en) 2001-07-19
NO20022457L (no) 2002-05-24
SK9302002A3 (en) 2002-11-06
EE200200267A (et) 2003-06-16
HRP20020460A2 (en) 2003-10-31
DK1235809T3 (da) 2004-03-15
DE19957156A1 (de) 2001-05-31
MXPA02003822A (es) 2002-12-13
DE50004455D1 (de) 2003-12-18
EA005681B1 (ru) 2005-04-28
UY26448A1 (es) 2001-06-29
CA2383114C (en) 2008-06-17
ATE254108T1 (de) 2003-11-15
AR026586A1 (es) 2003-02-19
ZA200204056B (en) 2003-07-30
ES2210036T3 (es) 2004-07-01
PT1235809E (pt) 2004-04-30
WO2001051471A1 (de) 2001-07-19
JP2003519687A (ja) 2003-06-24
EA200200491A1 (ru) 2002-12-26
BR0015786A (pt) 2002-08-13
CN1177825C (zh) 2004-12-01
IL149607A0 (en) 2002-11-10
HUP0204169A3 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
CA2425560A1 (en) Anticholinergics, processes for preparing them and their use as pharmaceutical compositions
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
YU27304A (sh) Novi dihidropteridinoni, postupak za njihovo dobijanje i njihova primena kao lekova
IL123293A0 (en) Piperidine derivatives their preparation and use
AP2002002637A0 (en) Novel piperazine
PL337329A1 (en) Oxazolydinone based antibacterial agents comprising a thiocarbonyl functional group
BG103485A (en) Ketobanzamides as calpain inhibitors
MY138525A (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
BG106340A (en) Substituted oxoazaheterocyclyl compounds
MY134582A (en) New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
GR3036305T3 (en) Chiral methyl phenyl oxazolidinones
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
YU30603A (sh) Derivati premošćenog piperazina
CA2322195A1 (en) Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
MX9803672A (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
BG105766A (en) New process for preparing pesticidal intermediates
MX9601635A (es) Derivados de antraciclina.
BG106002A (en) Process for preparing pesticidal intermediates
NZ332545A (sh)
IN187760B (sh)
MXPA02001406A (es) Heterociclilos-2h-cromenos substituidos.
YU37902A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3- benzazocini i njihova primena kao lekova
BG105326A (en) Novel benzoylguanadine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
GB9920959D0 (en) Novel process